Belgian drugmaker UCB (Euronext: UCB) has presented what it calls its ‘growth journey’ and the strategic priorities driving future success at the 43rd JP Morgan (JPM) Healthcare Conference in San Francisco, USA.
The company, which has a focus on developing solutions in immunology and neurology, has now predicted a decade-plus of growth.
Jean-Christophe Tellier, chief executive of UCB, said: “At UCB, we are looking ahead with confidence and determination. We will continue to deliver differentiated innovation, transforming what is possible for patients, caregivers, medical professionals and shareholders.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze